Prospective study on anti-ganglioside antibodies in childhood Guillain-Barre syndrome

Scheßl, J.; Koga, Michiaki; Funakoshi, Kengo; Kirschner, Janbernd; Muellges, Wolfgang; Weishaupt, Andreas; Gold, Ralf; Korinthenberg, Rudolf

doi:10.1136/adc.2006.098061

Cited by 34 publications

(15 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The link between antiganglioside antibodies and axonal forms has been demonstrated in numerous studies. [13][14][15][16] One of our key findings is that the axonal form (AMAN or AMSAN) has a higher risk of long-term sequelae, consistent with other studies. 17,18 However, these results must be interpreted with caution because other studies 8,11,19,20 have shown that, although the axonal forms have a slower recovery period than the demyelinating forms, there was no long-term difference between the two groups.…”

Section: Discussionsupporting

confidence: 90%

See 1 more Smart Citation

Prognostic factors for the sequelae and severity of Guillain‐Barré syndrome in children

et al. 2019

View full text Add to dashboard Cite

Introduction Guillain‐Barré syndrome (GBS) is an inflammatory polyradiculoneuritis. Our aim in this study was to describe the clinical characteristics and the long‐term sequelae of GBS in a French pediatric population. Methods In this multicenter, retrospective study we evaluated clinical signs, radiological examinations, laboratory tests, treatments, and outcomes. Results One hundred ten children were included in this investigation. These children presented with walking difficulties, muscle weakness, and cranial nerve impairment. Electrodiagnostic testing revealed 70% with acute inflammatory demyelinating polyradiculoneuropathy (AIDP) and 16% with acute motor axonal neuropathy (AMAN). One hundred children received immunoglobulins. At follow‐up, 77% were cured, whereas 9% had sequelae, associated with an axonal form (P < .01) and a short interval between symptom onset and hospitalization (P < .01). The need for intubation was correlated with peripheral facial paralysis (P < .01) and dysautonomia (P < .01). Discussion Although AIDP and AMAN present in a similar way, the axonal form is associated with a worse outcome.

show abstract

Section: Discussionsupporting

confidence: 90%

“…In our cohort, we highlight a significant correlation between the presence of an axonal form and the presence of antiganglioside antibodies and, more specifically, with anti‐GM1 antibodies. The link between antiganglioside antibodies and axonal forms has been demonstrated in numerous studies …”

Section: Discussionmentioning

confidence: 91%

Prognostic factors for the sequelae and severity of Guillain‐Barré syndrome in children

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Children with GBS are presumed to have a faster and better recovery than adults, although the long‐term disability and impact of childhood GBS have not been well defined (Vajsar et al, ; Korinthenberg et al, ; Ortiz‐Corredor and Peña‐Preciado, ; Schessl et al, ; McGrogan et al, ; Rabie and Nevo, ) . Case series in children with GBS report symptoms of weakness, numbness, paresthesias, pain, dyscoordination, and fatigue (Vajsar et al, ; Korinthenberg et al, ; Rabie and Nevo, ) which may persist for months (Nagasawa et al, ) .…”

Section: Introductionmentioning

confidence: 99%

Long‐term outcome of Guillain‐Barré syndrome in children

Roodbol

Wit

Aarsen

et al. 2014

J Peripheral Nervous Sys

View full text Add to dashboard Cite

The objective of this study is to determine the long-term outcome and consequences of Guillain-Barré syndrome (GBS) in children. This is an observational cross-sectional cohort study of children diagnosed with GBS (0-18 years old) at the Sophia Children's Hospital in Rotterdam from 1987 to 2009. All patients were invited for a structured interview, questionnaires, and full neurologic exam to record their current clinical condition focused on complaints and symptoms, neurological deficits, disabilities, behavior, and quality of life. Thirty-seven patients participated, 23 were now adults, with a median age of 20 years (range 4-39 years) and a median follow-up time of 11 years (range 1-22 years). Residual complaints were reported by 24 (65%) patients, including paresthesias (38%), unsteadiness of gait in the dark (37%), painful hands or feet (24%), and severe fatigue (22%). Four patients had severe neurological deficits, including facial diplegia and limb weakness. Two patients had had a recurrence of GBS. In 10 patients (26%), GBS had a negative impact on their school career. Questionnaires identified a wide range of behavioral problems. Quality of life was below normal on the subscale vitality, and above normal on the subscales social functioning and positive emotions in the adult group. Most children show good recovery of neurological deficits after GBS, but many have persisting long-term residual complaints and symptoms that may lead to psychosocial problems interfering with participation in daily life.

show abstract

“…In a German study investigating antiganglioside antibodies in childhood GBS, no significant differences were found as compared with adult GBS. The overall lower detected prevalence of antibody positive cases (11%) is likely to represent the high cut-off level used to define a positive sample by ELISA [42], and highlights one of the pitfalls in comparing results from different laboratories.…”

Section: Clinical Seriesmentioning

confidence: 96%